Actively Recruiting

Phase 3
Age: 18Years - 130Years
All Genders
NCT06346392

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Led by AstraZeneca · Updated on 2026-03-09

572

Participants Needed

186

Research Sites

132 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

CONDITIONS

Official Title

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Who Can Participate

Age: 18Years - 130Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to provide signed informed consent before any study procedures.
  • At least 18 years old or legal age of consent in the study location.
  • Histologically confirmed unresectable, locally advanced, or metastatic adenocarcinoma of gastric, gastroesophageal junction, or distal esophagus.
  • Positive CLDN18.2 expression from tumor samples collected within the past 24 months or from a fresh biopsy.
  • Disease progression after at least one prior line of treatment for advanced or metastatic disease, including fluoropyrimidine and platinum.
  • At least one measurable or evaluable lesion based on RECIST 1.1.
  • ECOG performance status of 0 or 1 without deterioration in the previous 2 weeks before baseline or first dosing.
  • Predicted life expectancy of at least 12 weeks.
  • Adequate organ and bone marrow function.
  • Body weight of at least 35 kg.
  • Meet sex and contraceptive requirements as specified.
Not Eligible

You will not qualify if you...

  • Known HER2 positive status defined by IHC or ISH testing.
  • Significant or unstable gastric bleeding or untreated gastric ulcers.
  • Central nervous system metastases or serious CNS conditions including epilepsy, seizures, brain injury, dementia, Parkinson's disease, neurodegenerative diseases, or severe mental illness within 3 months prior to consent.
  • Clinically significant corneal disease such as active keratitis or corneal ulcerations.
  • Persistent toxicities from prior anticancer therapy graded 2 or higher, excluding hair loss, unless irreversible and stable.
  • Previous treatment with any ADC containing MMAE or CLDN18.2-targeting therapies other than naked monoclonal antibodies.
  • History of venous thromboembolism within 6 months before randomization (except stable cases) or arterial thromboembolism within 12 months before randomization.
  • Any other disease or condition deemed by the investigator to make participation undesirable or unsafe.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 186 locations

1

Research Site

Birmingham, Alabama, United States, 35233

Withdrawn

2

Research Site

Mobile, Alabama, United States, 36604

Active, Not Recruiting

3

Research Site

Tucson, Arizona, United States, 85719

Active, Not Recruiting

4

Research Site

Duarte, California, United States, 91010

Active, Not Recruiting

5

Research Site

Fullerton, California, United States, 92835

Withdrawn

6

Research Site

Irvine, California, United States, 92618

Active, Not Recruiting

7

Research Site

Los Angeles, California, United States, 90048

Active, Not Recruiting

8

Research Site

Los Angeles, California, United States, 90089

Active, Not Recruiting

9

Research Site

Newport Beach, California, United States, 92663

Actively Recruiting

10

Research Site

Santa Rosa, California, United States, 95403

Withdrawn

11

Research Site

Washington D.C., District of Columbia, United States, 20007

Active, Not Recruiting

12

Research Site

Fleming Island, Florida, United States, 32003

Withdrawn

13

Research Site

Hollywood, Florida, United States, 33021

Active, Not Recruiting

14

Research Site

Orlando, Florida, United States, 32804

Active, Not Recruiting

15

Research Site

Atlanta, Georgia, United States, 30322

Withdrawn

16

Research Site

Marietta, Georgia, United States, 30060

Active, Not Recruiting

17

Research Site

Honolulu, Hawaii, United States, 96819

Withdrawn

18

Research Site

Boise, Idaho, United States, 83712

Active, Not Recruiting

19

Research Site

Lexington, Kentucky, United States, 40536

Active, Not Recruiting

20

Research Site

Baltimore, Maryland, United States, 21287

Withdrawn

21

Research Site

Boston, Massachusetts, United States, 02114

Active, Not Recruiting

22

Research Site

Ann Arbor, Michigan, United States, 48106

Active, Not Recruiting

23

Research Site

Ann Arbor, Michigan, United States, 48109

Active, Not Recruiting

24

Research Site

Kansas City, Missouri, United States, 64111

Active, Not Recruiting

25

Research Site

St Louis, Missouri, United States, 63110

Withdrawn

26

Research Site

St Louis, Missouri, United States, 63128

Withdrawn

27

Research Site

Mineola, New York, United States, 11501

Active, Not Recruiting

28

Research Site

New York, New York, United States, 10016

Active, Not Recruiting

29

Research Site

New York, New York, United States, 10032

Active, Not Recruiting

30

Research Site

New York, New York, United States, 10065

Actively Recruiting

31

Research Site

Cincinnati, Ohio, United States, 45219

Withdrawn

32

Research Site

Portland, Oregon, United States, 97239

Withdrawn

33

Research Site

Philadelphia, Pennsylvania, United States, 19111

Active, Not Recruiting

34

Research Site

York, Pennsylvania, United States, 17403

Active, Not Recruiting

35

Research Site

Charlottesville, Virginia, United States, 22908

Active, Not Recruiting

36

Research Site

Fredericksburg, Virginia, United States, 22408

Active, Not Recruiting

37

Research Site

Olympia, Washington, United States, 98502

Active, Not Recruiting

38

Research Site

Seattle, Washington, United States, 98109

Withdrawn

39

Research Site

Porto Alegre, Brazil, 91350-200

Actively Recruiting

40

Research Site

Ribeirão Preto, Brazil, 14051-140

Actively Recruiting

41

Research Site

São Paulo, Brazil, 05652-900

Actively Recruiting

42

Research Site

Vitória, Brazil, 29043-272

Actively Recruiting

43

Research Site

Calgary, Alberta, Canada, T2N 4N2

Withdrawn

44

Research Site

Barrie, Ontario, Canada, L4M 6M2

Actively Recruiting

45

Research Site

London, Ontario, Canada, N6C 2R5

Actively Recruiting

46

Research Site

North York, Ontario, Canada, M2K 1E1

Actively Recruiting

47

Research Site

Ottawa, Ontario, Canada, K1H 8L6

Actively Recruiting

48

Research Site

Toronto, Ontario, Canada, M5G 2M9

Actively Recruiting

49

Research Site

Montreal, Quebec, Canada, H3G 1A4

Actively Recruiting

50

Research Site

Montreal, Quebec, Canada, H3T 1E2

Withdrawn

51

Research Site

Beijing, China, 100210

Actively Recruiting

52

Research Site

Changchun, China, 130021

Actively Recruiting

53

Research Site

Changsha, China, 410013

Withdrawn

54

Research Site

Chengdu, China, 610000

Actively Recruiting

55

Research Site

Chengdu, China, 610042

Actively Recruiting

56

Research Site

Fuzhou, China, 350001

Actively Recruiting

57

Research Site

Fuzhou, China, 350014

Actively Recruiting

58

Research Site

Guangzhou, China, 510060

Actively Recruiting

59

Research Site

Guangzhou, China, 510120

Actively Recruiting

60

Research Site

Guangzhou, China, 510655

Actively Recruiting

61

Research Site

Guangzhou, China, 510700

Actively Recruiting

62

Research Site

Hangzhou, China, 310020

Actively Recruiting

63

Research Site

Hangzhou, China, 310022

Actively Recruiting

64

Research Site

Harbin, China, 150049

Actively Recruiting

65

Research Site

Hefei, China, 230022

Actively Recruiting

66

Research Site

Hefei, China, 230031

Actively Recruiting

67

Research Site

Hefei, China, 230601

Actively Recruiting

68

Research Site

Jinan, China, 250117

Actively Recruiting

69

Research Site

Jining, China, 272029

Actively Recruiting

70

Research Site

Lanzhou, China, 730000

Actively Recruiting

71

Research Site

Lishui, China, 323000

Actively Recruiting

72

Research Site

Luoyang, China, 471003

Withdrawn

73

Research Site

Nanjing, China, 210008

Actively Recruiting

74

Research Site

Nanjing, China, 210009

Withdrawn

75

Research Site

Qingdao, China, 266003

Actively Recruiting

76

Research Site

Shanghai, China, 200025

Actively Recruiting

77

Research Site

Shanghai, China, 200032

Actively Recruiting

78

Research Site

Shanghai, China, 200040

Actively Recruiting

79

Research Site

Shenyang, China, 110042

Actively Recruiting

80

Research Site

Shijiazhuang, China, 050011

Actively Recruiting

81

Research Site

Suzhou, China, 215004

Actively Recruiting

82

Research Site

Tianjin, China, 300060

Actively Recruiting

83

Research Site

Ürümqi, China, 830000

Suspended

84

Research Site

Wuhan, China, 430000

Actively Recruiting

85

Research Site

Wuhan, China, 430030

Actively Recruiting

86

Research Site

Xi'an, China, 710061

Actively Recruiting

87

Research Site

Yinchuan, China, 750004

Actively Recruiting

88

Research Site

Zhengzhou, China, 450003

Actively Recruiting

89

Research Site

Besançon, France, 25030

Actively Recruiting

90

Research Site

Brest, France, 29200

Active, Not Recruiting

91

Research Site

Lille, France, 59037

Actively Recruiting

92

Research Site

Lyon, France, 69008

Active, Not Recruiting

93

Research Site

Nantes, France, 44000

Actively Recruiting

94

Research Site

Paris, France, 75571

Actively Recruiting

95

Research Site

Poitiers, France, 86021

Actively Recruiting

96

Research Site

Berlin, Germany, 10249

Actively Recruiting

97

Research Site

Berlin, Germany, 13353

Actively Recruiting

98

Research Site

Dresden, Germany, 01067

Withdrawn

99

Research Site

Dresden, Germany, 01370

Withdrawn

100

Research Site

Essen, Germany, 45136

Withdrawn

101

Research Site

Frankfurt, Germany, 60488

Actively Recruiting

102

Research Site

Göttingen, Germany, 37075

Actively Recruiting

103

Research Site

Hamburg, Germany, 20246

Actively Recruiting

104

Research Site

Heidelberg, Germany, 69120

Actively Recruiting

105

Research Site

Heilbronn, Germany, 74078

Actively Recruiting

106

Research Site

Leipzig, Germany, 04103

Actively Recruiting

107

Research Site

Mainz, Germany, 55131

Withdrawn

108

Research Site

Marburg, Germany, 35043

Actively Recruiting

109

Research Site

Moers, Germany, 47441

Actively Recruiting

110

Research Site

München, Germany, 81377

Actively Recruiting

111

Research Site

Hong Kong, Hong Kong, 150001

Actively Recruiting

112

Research Site

Hong Kong, Hong Kong

Actively Recruiting

113

Research Site

Ahmedabad, India, 380015

Actively Recruiting

114

Research Site

Bengaluru, India, 560027

Withdrawn

115

Research Site

Hyderabad, India, 500032

Actively Recruiting

116

Research Site

Mumbai, India, 400012

Actively Recruiting

117

Research Site

New Delhi, India, 110085

Actively Recruiting

118

Research Site

Florence, Italy, 50134

Actively Recruiting

119

Research Site

Milan, Italy, 20133

Actively Recruiting

120

Research Site

Milan, Italy, 20162

Actively Recruiting

121

Research Site

Modena, Italy, 41124

Withdrawn

122

Research Site

Naples, Italy, 80131

Actively Recruiting

123

Research Site

Padova, Italy, 35128

Actively Recruiting

124

Research Site

Pisa, Italy, 56100

Actively Recruiting

125

Research Site

Vicenza, Italy, 36100

Actively Recruiting

126

Research Site

Fukuoka, Japan, 812-8582

Actively Recruiting

127

Research Site

Kashiwa, Japan, 227-8577

Actively Recruiting

128

Research Site

Kōtoku, Japan, 135-8550

Actively Recruiting

129

Research Site

Nagoya, Japan, 464-8681

Actively Recruiting

130

Research Site

Ogaki-shi, Japan, 503-8502

Actively Recruiting

131

Research Site

Osaka, Japan, 541-8567

Actively Recruiting

132

Research Site

Sunto-gun, Japan, 411-8777

Actively Recruiting

133

Research Site

Tokyo, Japan, 104-0045

Actively Recruiting

134

Research Site

Toyoake-shi, Japan, 470-1192

Actively Recruiting

135

Research Site

Yokohama, Japan, 241-8515

Actively Recruiting

136

Research Site

Bielsko-Biala, Poland, 43-300

Actively Recruiting

137

Research Site

Gdansk, Poland, 80-219

Actively Recruiting

138

Research Site

Katowice, Poland, 40-514

Active, Not Recruiting

139

Research Site

Krakow, Poland, 31-501

Actively Recruiting

140

Research Site

Lublin, Poland, 20-080

Actively Recruiting

141

Research Site

Szczecin, Poland, 71-730

Withdrawn

142

Research Site

Słupsk, Poland, 76-200

Active, Not Recruiting

143

Research Site

Tomaszów Mazowiecki, Poland, 97-200

Withdrawn

144

Research Site

Warsaw, Poland, 02-034

Actively Recruiting

145

Research Site

Warsaw, Poland, 04-141

Actively Recruiting

146

Research Site

Gyeonggi-do, South Korea, 13620

Actively Recruiting

147

Research Site

Seoul, South Korea, 03080

Actively Recruiting

148

Research Site

Seoul, South Korea, 03722

Actively Recruiting

149

Research Site

Seoul, South Korea, 05505

Active, Not Recruiting

150

Research Site

Seoul, South Korea, 06351

Actively Recruiting

151

Research Site

Seoul, South Korea, 06591

Actively Recruiting

152

Research Site

Barcelona, Spain, 08036

Actively Recruiting

153

Research Site

Barcelona, Spain, 8035

Actively Recruiting

154

Research Site

Madrid, Spain, 28034

Actively Recruiting

155

Research Site

Madrid, Spain, 28041

Actively Recruiting

156

Research Site

Ourense, Spain, 32005

Actively Recruiting

157

Research Site

Santander, Spain, 39008

Actively Recruiting

158

Research Site

Seville, Spain, 41013

Actively Recruiting

159

Research Site

Bern, Switzerland, 3010

Active, Not Recruiting

160

Research Site

Geneva, Switzerland, 1205

Active, Not Recruiting

161

Research Site

Lausanne, Switzerland, 1011

Active, Not Recruiting

162

Research Site

Zurich, Switzerland, 8032

Active, Not Recruiting

163

Research Site

Kaohsiung City, Taiwan, 00807

Actively Recruiting

164

Research Site

Kaohsiung City, Taiwan, 83301

Actively Recruiting

165

Research Site

Taichung, Taiwan, 40447

Actively Recruiting

166

Research Site

Tainan, Taiwan, 704

Actively Recruiting

167

Research Site

Taipei, Taiwan, 10002

Actively Recruiting

168

Research Site

Taipei, Taiwan, 112

Actively Recruiting

169

Research Site

Taoyuan, Taiwan, 333

Actively Recruiting

170

Research Site

Bangkok, Thailand, 10700

Active, Not Recruiting

171

Research Site

Dusit, Thailand, 10300

Active, Not Recruiting

172

Research Site

Hat Yai, Thailand, 90110

Active, Not Recruiting

173

Research Site

Khon Kaen, Thailand, 40002

Active, Not Recruiting

174

Research Site

Ankara, Turkey (Türkiye), 06230

Actively Recruiting

175

Research Site

Diyarbakır, Turkey (Türkiye), 21280

Actively Recruiting

176

Research Site

Erzurum, Turkey (Türkiye), 25240

Actively Recruiting

177

Research Site

Istanbul, Turkey (Türkiye), 34098

Actively Recruiting

178

Research Site

Cambridge, United Kingdom, CB2 0QQ

Actively Recruiting

179

Research Site

London, United Kingdom, EC1A 7BE

Actively Recruiting

180

Research Site

London, United Kingdom, SW3 6JJ

Actively Recruiting

181

Research Site

Manchester, United Kingdom, M20 4BX

Actively Recruiting

182

Research Site

Oxford, United Kingdom, OX3 7LE

Actively Recruiting

183

Research Site

Taunton, United Kingdom, TA1 5DA

Actively Recruiting

184

Research Site

Hanoi, Vietnam, 100000

Actively Recruiting

185

Research Site

Ho Chi Minh City, Vietnam, 700000

Actively Recruiting

186

Research Site

Vinh, Vietnam, 460000

Actively Recruiting

Loading map...

Research Team

A

AstraZeneca Clinical Study Information Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | DecenTrialz